Volume 5 Issue 2
Dec.  2021
Turn off MathJax
Article Contents
Yan Peng, Zhenqing Feng. The progress and perspectives of CAR-T cell therapy[J]. Blood&Genomics, 2021, 5(2): 107-111. doi: 10.46701/BG.2021022021126
Citation: Yan Peng, Zhenqing Feng. The progress and perspectives of CAR-T cell therapy[J]. Blood&Genomics, 2021, 5(2): 107-111. doi: 10.46701/BG.2021022021126

The progress and perspectives of CAR-T cell therapy

doi: 10.46701/BG.2021022021126
More Information
  • Corresponding author: Zhenqing Feng, National Health Commission Key Lab. of Antibody Techniques, Nanjing Medical University, Nanjing, Jiangsu 211166, China. E-mail: fengzhenqing@njmu.edu.cn
  • Received Date: 2021-09-26
  • Accepted Date: 2021-11-19
  • Rev Recd Date: 2021-11-16
  • Available Online: 2022-01-06
  • Publish Date: 2021-12-31
  • CAR-T cell therapy has already achieved world-renowned clinical effects in the treatment of hematological malignancies. Due to the tumor heterogeneity, immunosuppressive microenvironment, and other factors, CAR-T cell therapy has still not shown obvious clinical efficacy in clinical treatment of solid tumors. However, great progress has been made in the preparation of CAR-T cells in recent years, including T cells redirected for universal cytokine mediated killing, universal CAR -T cells, non-viral vector CAR-T cells, SynNotch technology, SUPRA CAR technology, regulated CAR-T cells, and bi-specific CAR-T cells, etc. Future research and development of CAR-T cell therapy will be focused on these following aspects: the combined application of CAR-T cells with different targets, known as "Cocktail CAR-T cells", is expected to increase efficiency toward solid tumors; based on systemic biology/synthetic biology theories, CAR-T cells are likely to be transformed to robot or intelligent system by introducing sensors, logic gates, and logic circuits. This article mainly comments on research progress and perspectives on CAR-T cell therapy in solid tumor treatment.


  • loading
  • [1]
    Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy[J]. N Engl J Med, 2016, 375(26): 2561−2569. doi: 10.1056/NEJMoa1610497
    Zimmermann K, Kuehle J, Dragon AC, et al. Design and characterization of an “All-in-One” lentiviral vector system combining constitutive anti-GD2 CAR expression and inducible cytokines[J]. Cancers, 2020, 12(2): 375. doi: 10.3390/cancers12020375
    Dragon AC, Zimmermann K, Nerreter T, et al. CAR-T cells and TRUCKs that recognize an EBNA-3C-derivedepitope presented on HLA-B*35control Epstein-Barrvirus-associated lymphoproliferation[J]. J Immunother Cancer, 2020, 8(2): e000736. doi: 10.1136/jitc-2020-000736
    Adachi K, Kano Y, Nagai T, et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor[J]. Nat Biotechnol, 2018, 36(4): 346−351. doi: 10.1038/nbt.4086
    Duan D, Wang K, Wei C, et al. The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma[J]. Front Immunol, 2021, 12: 609421. doi: 10.3389/fimmu.2021.609421
    Pang N, Shi J, Qin L, et al. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin[J]. J Hematol Oncol, 2021, 14(1): 118. doi: 10.1186/s13045-021-01128-9
    Batra SA, Rathi P, Guo L, et al. Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma[J]. Cancer Immunol Res, 2020, 8(3): 309−320. doi: 10.1158/2326-6066.CIR-19-0293
    Zhao J, Lin Q, Song Y, et al. Universal CARs, universal T cells, and universal CAR T cells[J]. J Hematol Oncol, 2018, 11(1): 132. doi: 10.1186/s13045-018-0677-2
    Hou JZ, Ye JC, Pu JJ, et al. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting[J]. J Hematol Oncol, 2021, 14(1): 66. doi: 10.1186/s13045-021-01077-3
    Lin H, Cheng J, Mu W, et al. Advances in universal CAR-T cell therapy[J]. Front Immunol, 2021, 12: 744823. doi: 10.3389/fimmu.2021.744823
    Zhang Y, Li P, Fang H, et al. Paving the way towards universal chimeric antigen receptor therapy in cancer treatment: current landscape and progress[J]. Front Immunol, 2020, 11: 604915. doi: 10.3389/fimmu.2020.604915
    Anon. Universal CAR T cells treat leukemia[J]. Cancer Discov, 2017, 7(4): 342. doi: 10.1158/2159-8290.CD-NB2017-023
    Hu Y, Zhou Y, Zhang M, et al. CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia[J]. Clin Cancer Res, 2021, 27(10): 2764−2772. doi: 10.1158/1078-0432.CCR-20-3863
    Li S, Wang X, Yuan Z, et al. Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management[J]. Clin Cancer Res, 2021, 27(5): 1242−1246. doi: 10.1158/1078-0432.CCR-20-1271
    Wermke M, Kraus S, Ehninger A, et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML[J]. Blood, 2021, 137(22): 3145−3148. doi: 10.1182/blood.2020009759
    Yang LR, Li L, Meng MY, et al. Evaluation of piggyBac-mediated anti-CD19 CAR-T cells after ex vivo expansion with aAPCs or magnetic beads[J]. J Cell Mol Med, 2021, 25(2): 686−700. doi: 10.1111/jcmm.16118
    Chicaybam L, Bonamino MH, Luckow Invitti A, et al. Overhauling CAR T cells to improve efficacy, safety and cost[J]. Cancers (Basel), 2020, 12(9): 2360. doi: 10.3390/cancers12092360
    Roybal KT, Rupp LJ, Morsut L, et al. Precision tumor recognition by T Cells with combinatorial antigen-sensing circuits[J]. Cell, 2016, 164(4): 770−779. doi: 10.1016/j.cell.2016.01.011
    Wu MR, Jusiak B, Lu TK, et al. Engineering advanced cancer therapies with synthetic biology[J]. Nat Rev Cancer, 2019, 19(4): 187−195. doi: 10.1038/s41568-019-0121-0
    Cho JH, Collins JJ, Wong WW, et al. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses[J]. Cell, 2018, 173(6): 1426−1438.e1411. doi: 10.1016/j.cell.2018.03.038
    Moghimi B, Muthugounder S, Jambon S, et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma[J]. Nat Commun, 2021, 12(1): 511. doi: 10.1038/s41467-020-20785-x
    Raj D, Yang MH, Rodgers D, et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma[J]. Gut, 2019, 68(6): 1052−1064. doi: 10.1136/gutjnl-2018-316595
    Rodgers DT, Mazagova M, Hampton EN, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies[J]. Proc Natl Acad Sci, 2016, 113(4): E459−E468. doi: 10.1073/pnas.1524155113
    Zhao W, Jia LZ, Zhang MJ, et al. The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer[J]. Am J Cancer Res, 2019, 9(8): 1846–1856.
    Zhang W, Huang Q, Xiao W, et al. Advances in anti-tumor treatments targeting the CD47/SIRPalpha axis[J]. Front Immunol, 2020, 11: 18. doi: 10.3389/fimmu.2020.00018
    Shu R, Evtimov VJ, Hammett MV, et al. Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer[J]. Mol Ther Oncolytics, 2021, 20: 325−341. doi: 10.1016/j.omto.2021.01.002
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (18) PDF downloads(0) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint